Defluorinated canagliflozin compound, and preparation method and application thereof

A deflucagliflozin and reaction technology, applied in organic chemistry, measuring devices, instruments, etc., can solve problems affecting drug efficacy, side effects, etc.

Inactive Publication Date: 2016-04-20
BEIJING PUDEKANGLI PHARMA TECH DEV CO LTD
View PDF8 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The content of the active ingredient of a drug is an important indicator of the purity of the drug, and the impurities in the drug directly affect the efficacy of the drug and may cause toxic and side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Defluorinated canagliflozin compound, and preparation method and application thereof
  • Defluorinated canagliflozin compound, and preparation method and application thereof
  • Defluorinated canagliflozin compound, and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Preparation of desflucagliflozin compound

[0039]A: Add toluene (10L) into a 20L glass reactor, start stirring, and add 2-[(5-bromo-2-methylphenyl)methyl]-5-phenylthiophene and sodium iodide sequentially under nitrogen protection , Cuprous iodide. After stirring for 15 minutes, N,N-dimethylethylenediamine and diglyme were added, and the reaction solution was heated to 85-90° C. and stirred for 36 hours. Cool down to 45-50°C, add activated carbon, stir at the same temperature for 1 hour, cool down to 25-30°C and filter, add the filtrate into a 50L reaction kettle filled with ethyl acetate. Wash once with 5% ammonia water, separate the organic layer, wash once with purified water, separate the layers, dry the organic phase with anhydrous sodium sulfate for 2 hours, filter, and concentrate the filtrate under reduced pressure at 35-40°C. Add the concentrated solution into methanol, stir at 70-75°C for 2 hours, cool, wait until the temperature drops to 20-25°C, filter, wa...

Embodiment 2

[0054] Desflucagliflozin compound detection method

[0055] Chromatographic conditions: octadecylsilane bonded silica gel as filler, mobile phase A is acetonitrile-water (0.02% trifluoroacetic acid) (10:90), mobile phase B is acetonitrile-water (0.02% trifluoroacetic acid) (90︰10), the gradient elution is as follows:

[0056]

[0057] Column temperature: 45, °C flow rate: 1.0ml / min, injection volume: 20μl, detection wavelength: 290nm. The number of theoretical plates is not less than 2000 based on the net calculation of canagliflozin.

[0058] Assay method: accurately weigh the appropriate amount of composition fine powder (equivalent to canagliflozin C 24 h 25 FO 5 S. 1 / 2 h 2 (2.12.5mg), in the 25ml measuring bottle, add 0.025mg / ml desflecagliflozin stock solution 1ml, add solvent and be diluted to scale, shake up, filter, get continued filtrate as need testing solution. Precisely measure 20 μl of the test solution, inject it into the liquid chromatograph, and re...

Embodiment 3

[0060] Desflucagliflozin as a reference substance for the determination of related substances in canagliflozin raw materials

[0061] Measure according to high performance liquid chromatography (Chinese Pharmacopoeia 2010 edition two appendix Ⅴ D), chromatographic conditions with reference to embodiment 2.

[0062] Preparation of the test solution Weigh about 12.5mg of this product, weigh it accurately, put it in a 25ml measuring bottle, dissolve it with acetonitrile-water (50:50) and dilute to the mark, shake well, and you get it.

[0063] Preparation of desflucagliflozin reference substance solution Take an appropriate amount of desflucagliflozin reference substance, accurately weighed, dissolve and dilute into a 0.75 μg / ml solution with acetonitrile-water (50:50), as desflucagliflozin Gliflozin reference substance solution.

[0064] Determination method Precisely measure 20 μl of the test solution and the control solution, inject them into the liquid chromatograph, and rec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a defluorinated canagliflozin compound as shown in a formula (I) which is described in the specification, and a preparation method thereof. Moreover, the invention also provides application of defluorinated canagliflozin as a standard reference substance. According to the invention, the quality of a canagliflozin product is effectively controlled, so safety and validity of a canagliflozin preparation in clinical usage are guaranteed.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry, and more specifically relates to an impurity compound in canagliflozin-desflucagliflozin and its preparation method and application. Background technique [0002] Canagliflozin (trade name INVOKANA TM , Canagliflozin) is a selective sodium glucose co-transporter 2 (sodiumglucoseco-transporter2, SGLT2) inhibitor developed by Janssen, a Johnson & Johnson company, for the treatment of adults with type 2 diabetes to improve blood sugar control. It is currently approved in the US and EU for the treatment of type 2 diabetes. [0003] Its chemical name is (1S)-1,5-dehydro-1-C-[3-[[5-phenyl-2-thienyl]methyl]-4-methylphenyl]-D-glucitol hemihydrate. [0004] The structural formula is shown in the following formula [0005] [0006] The content of the active ingredient of a drug is an important symbol reflecting the purity of the drug, and the impurities in the drug directly affect the efficacy of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D409/10G01N30/02
CPCC07D409/10G01N30/02
Inventor 王娟赵拨杨彦华刘福春
Owner BEIJING PUDEKANGLI PHARMA TECH DEV CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap